Dasatinib-induced pulmonary arterial hypertension – A rare late complication. (April 2019)

• Record Type: Journal Article
• Authors: Ibrahim, Uroosa; Saqib, Amina; Dhar, Vidhya; Odaimi, Marcel
• Is Part Of: Journal of oncology pharmacy practice. Volume 25:Number 3(2019)
• Page Start: 727
• Page End: 730
• Publication Date: 2019-04
• Subjects: Chronic myeloid leukemia -- CML -- dasatinib -- pulmonary arterial hypertension -- tyrosine kinase inhibitor; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155217753740
• Languages: English
• ISSNs: 1078-1552

Abstract

Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. Pulmonary arterial hypertension is defined by an increase in mean pulmonary arterial pressure >25 mmHg at rest. Dasatinib-induced pulmonary hypertension has been reported in less than 1% of patients on chronic dasatinib treatment for chronic myelogenous leukemia. The pulmonary arterial hypertension from dasatinib may be categorized as either group 1 (drug-induced) or group 5 based on various mechanisms that may be involved including the pathogenesis of the disease process of chronic myelogenous leukemia. There have been reports of dasatinib-induced pulmonary arterial hypertension being reversible. We report a case of pulmonary arterial hypertension in a 46-year-old female patient with chronic phase chronic myelogenous leukemia on dasatinib treatment for over 10 years. She had significant improvement in symptoms after discontinuation of dasatinib and initiation of vasodilators. Several clinical questions arise once patients experience significant adverse effects as discussed in our case.